RE: RE: Strategic Transactions Part 3 By all means ISA is a speculation. When these strange birds with "intriguing credentials" appeared on the BOD, surely ISA got back my attention. Personally, I don't think that these directors are commited to ISA, I think,they are on the board to serve their own respective companies. Well, ISA is priced cheap in the relationship to the future potential profits from this generic ( patent protected ) drug. Again, this is speculation, but it might make financial sense for companies invested in ISA , to protect their investments by buying out ISA, early, before end of a phase 3 double blinded studies. One could argue that recent fact of not letting ILJIN to increase ownership of ISA protects the money that other companies invested in. Also, ISA stock has minimal daily float, therefore the share prices can be easily manipulated, at least for now. And I'm pretty sure that most of retailers will sell happily their holdings in twenties (cents) as of lets say today. However, assuming that phase 3 studies are concluded successfuly, then there is strong possibility that the prices will go way up north ( plus, might also show up another suitor ). Concluding, while voclosporin probably will see end of the phase 3, I wouldn't be so sure about existance of ISA at the same time. Again and again, these are speculations, and I wouldn't try to put numerical value to the probability of this happening. Cheers and GL to everybody.